June 19th 2025
Investigators of a study used a systematic review and meta-analysis to evaluate the risk of major adverse cardiac events related to cannabis by using real-world data.
Managing Iron Replacement Therapies for Patients With Inflammatory Bowel Disease
June 24, 2025 | 1:00 PM EDT & 8:00 PM EDT
View More
Recent Developments in the Management of Heart Failure With Preserved Ejection Fraction
1.0 Credit / Cardiology
View More
Therapies in Lowering LDL-Cholesterol Levels for the Primary and Secondary Prevention of Atherosclerotic Cardi...
0.75 Credit / Cardiology
View More
Updated Guidelines in the Management of Atrial Fibrillation and Application for Pharmacists
1.5 Credits / Cardiology
View More
Elevating Cardiac Care: Insights From Pharmacists Across Practice Settings
1.0 Credit / Cardiology
View More
The Expanding Role of Nonstatin Therapies in Reducing LDL-Cholesterol Levels to Prevent and Manage ASCVD: A Re...
1.5 Credits / Cardiology
View More
The Evolving Treatment Paradigm for the Management of Pulmonary Arterial Hypertension: Strategies to Optimize ...
1.5 Credits / Cardiology
View More
Lipoprotein(a) and Beyond: Emerging Paradigms in Atherosclerotic Cardiovascular Disease Prevention
1.5 Credits / Cardiology
View More
Optimizing Care for Chronic Worsening Heart Failure: The Key Role of Pharmacists in Integrating Therapies
1.5 Credits / Cardiology
View More
Iron Deficiency Anemia Treatment Considerations in Women’s Health
June 25, 2025 | 11:00 AM ET & 7:00 PM ET
View More
Exploring ATTR Phenotypes and Identifying Appropriate Opportunities for Pharmacists to Intervene
June 25, 2025 | 1:00 PM & 8:00 PM ET
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Harnessing the Potential of SGLT2 Inhibitors in Cardiorenal Metabolic Health: Strategies for Long-term Care an...
1.0 Credit / Cardiology, Endocrinology, Diabetes, & Metabolism, Nephrology
View More
Mastering Hypertrophic Cardiomyopathy: Cutting-Edge Therapies for Better Outcomes
1.5 Credits / Cardiology
View More
Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy
1.0 Credit / Cardiology
View More
Exploring Advances in the Management of DOAC-Associated Bleeding With Reversal Agents: Role of the Health-Syst...
1.5 Credits / Cardiology, Patient Safety
View More
Optimizing LDL-C Lowering and Adherence to Hyperlipidemia Guidelines
1.0 Credit / Cardiology
View More
Hyperlipidemia Overview and the Clinical and Economic Burden
1.0 Credit / Cardiology
View More
Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence
0.5 Credit / Cardiology
View More
The Role of the Pharmacist in the Management of Hyperlipidemia
1.0 Credit / Cardiology
View More
Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative
1.5 Credits / Cardiology
View More
The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies
1.5 Credits / Cardiology, Rare Diseases
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies
1.5 Credits / Pulmonology, Cardiology, Rare Diseases
View More
Advancing Stroke Prevention: The Pharmacist’s Role in Implementing the 2024 Guidelines
1.0 Credit / Cardiology
View More
The Role of IV Iron in Resolving Iron Deficiency in Heart Failure
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
From Guidelines to Practice: The Pharmacist’s Role in Chronic Heart Failure Therapy Optimization
1.5 Credits / Cardiology
View More
FDA OKs Dapagliflozin for Heart Failure With Reduced Ejection Fraction
May 6th 2020Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.